For help on how to get the results you want, see our search tips.
2 results
Keyword Remove keyword
Categories
Human Remove Human filter
Medicine
Paediatric investigation plans Remove Paediatric investigation plans filter
Referrals Remove Referrals filter
Medicine type
Biosimilar Remove Biosimilar filter
Exceptional circumstances Remove Exceptional circumstances filter
Generic Remove Generic filter
Orphan medicine Remove Orphan medicine filter
Accelerated assessment Remove Accelerated assessment filter
Referral status
Procedure started Remove Procedure started filter
European Commission final decision Remove European Commission final decision filter
Referral PRAC recommendation
Risk minimisation measures Remove Risk minimisation measures filter
-
List item
Referral: Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)
daclatasvir, dasabuvir, sofosbuvir, ledipasvir, simeprevir, ombitasvir, paritaprevir, ritonavir, associated names: Sovaldi, Olysio, Viekirax, Harvoni, Exviera, Daklinza, Article 20 procedures
Status: European Commission final decision, opinion/position date: 15/12/2016, EC decision date: 23/02/2017, Last updated: 09/03/2017 -
List item
Referral: Zynteglo
betibeglogene autotemcel, associated names: Zynteglo, Article 20 procedures
Status: European Commission final decision, opinion/position date: 22/07/2021, EC decision date: 16/09/2021, Last updated: 08/07/2022